Novo’s Inversago takeout brings another appetite and glucose modulator to its obesity arsenal

Novo’s acquisition of Canadian biotech Inversago brings the pharma another molecular target with effects on food intake and glucose homeostasis, and is a vote of confidence that peripherally acting agents targeting CB1 receptor won’t have the safety issues of first-generation compounds.

Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) announced Thursday it plans to acquire Inversago Pharma Inc. in a deal valued up to $1.1 billion if all development and commercial milestones are met. The deal is expected to close by year-end; details were not disclosed...